We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

447 hedge funds and large institutions have $10.1B invested in Royalty Pharma in 2025 Q1 according to their latest regulatory filings, with 84 funds opening new positions, 160 increasing their positions, 149 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

160% more call options, than puts

Call options by funds: $89M | Put options by funds: $34.2M

68% more first-time investments, than exits

New positions opened: 84 | Existing positions closed: 50

22% more capital invested

Capital invested by funds: $8.21B → $10.1B (+$1.84B)

7% more funds holding

Funds holding: 416 → 447 (+31)

2.07% more ownership

Funds ownership: 72.43% → 74.49% (+2.1%)

7% more repeat investments, than reductions

Existing positions increased: 160 | Existing positions reduced: 149

22% less funds holding in top 10

Funds holding in top 10: 9 → 7 (-2)

Holders
447
Holders Change
+31
Holders Change %
+7.45%
% of All Funds
5.99%
Holding in Top 10
7
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-22.22%
% of All Funds
0.09%
New
84
Increased
160
Reduced
149
Closed
50
Calls
$89M
Puts
$34.2M
Net Calls
+$54.8M
Net Calls Change
+$39.9M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$413M
2
CIA
Caledonia Investments (Australia)
Australia
+$162M
3
Victory Capital Management
Victory Capital Management
Texas
+$83.8M
4
Morgan Stanley
Morgan Stanley
New York
+$47.5M
5
Los Angeles Capital Management
Los Angeles Capital Management
California
+$33M

Top Sellers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$340M
2
Millennium Management
Millennium Management
New York
-$66.8M
3
SGA
Siguler Guff Advisers
New York
-$60.4M
4
Deutsche Bank
Deutsche Bank
Germany
-$56.3M
5
Viking Global Investors
Viking Global Investors
Connecticut
-$52.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
CPC
251
Cookson Peirce & Co
Pennsylvania
$688K +$700K +22,092 New
Ameriprise
252
Ameriprise
Minnesota
$684K -$71.5K -2,256 -9%
KAS
253
Kestra Advisory Services
Texas
$662K -$10.7K -337 -2%
EP
254
Edgestream Partners
New Jersey
$659K +$671K +21,158 New
SI
255
Sava Infond
Slovenia
$654K – – –
FRM
256
Fox Run Management
Connecticut
$643K -$1.09M -34,416 -63%
Carson Wealth (CWM LLC)
257
Carson Wealth (CWM LLC)
Nebraska
$642K +$377K +11,883 +136%
AB
258
Amalgamated Bank
New York
$636K +$27.4K +866 +4%
AAM
259
Advisors Asset Management
Colorado
$624K -$5.64K -178 -0.9%
LA
260
LBP AM
France
$623K – – –
Prudential Financial
261
Prudential Financial
New Jersey
$620K +$49.7K +1,567 +9%
RI
262
Ridgewood Investments
New Jersey
$612K -$351K -11,087 -36%
CSP
263
Cary Street Partners
Virginia
$610K +$621K +19,580 New
ProShare Advisors
264
ProShare Advisors
Maryland
$609K -$47.4K -1,495 -7%
SOMRS
265
State of Michigan Retirement System
Michigan
$604K – – –
Principal Financial Group
266
Principal Financial Group
Iowa
$591K -$36.3K -1,146 -6%
Stifel Financial
267
Stifel Financial
Missouri
$590K +$56.9K +1,794 +10%
Assenagon Asset Management
268
Assenagon Asset Management
Luxembourg
$576K -$18.2K -574 -3%
ECP
269
Epacria Capital Partners
Colorado
$574K -$23.8K -750 -4%
MSRPS
270
Maryland State Retirement & Pension System
Maryland
$569K -$131K -4,133 -18%
RBI
271
Raiffeisen Bank International
Austria
$565K -$63.4K -2,000 -10%
OSAM
272
O'Shaughnessy Asset Management
Connecticut
$560K +$570K +17,985 New
Nomura Holdings
273
Nomura Holdings
Japan
$557K +$568K +17,907 New
AC
274
Allstate Corporation
Illinois
$555K +$193K +6,103 +52%
RCAG
275
Rehmann Capital Advisory Group
Michigan
$549K +$559K +17,649 New
9 10
11
12 13

RPRX Hedge Fund Activity: Q1 2025 in Review

447 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q1 2025, worth a combined $10.1B — up 22% from $8.21B a quarter earlier.

Buyers outnumbered sellers: 84 funds opened new RPRX positions and 50 closed out — a net gain of 34 holders — while 160 added to existing stakes and 149 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $413M. The largest seller was Adage Capital Partners, cutting an estimated $340M.

  • 447 institutional investors held Royalty Pharma (RPRX) as of Q1 2025, up from 416 in Q4 2024.
  • Funds reported $10.1B of Royalty Pharma stock for Q1 2025, up 22% quarter-over-quarter.
  • 84 funds opened new Royalty Pharma positions in Q1 2025 and 50 closed out, a net change of +34 holders.
  • The largest Royalty Pharma buyer in Q1 2025 was Fidelity Investments, an estimated $413M added.
  • The largest Royalty Pharma seller in Q1 2025 was Adage Capital Partners, an estimated $340M sold.

Based on aggregated 13F filings for Q1 2025.